


US application Serial No. 09/840,503
Attorney Docket No. QA231

IN THE CLAIMS:

Please amend the claims as follows:

10. (currently amended) A compound of formula (I)



(I)

~~including~~ enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof wherein:

X¹ is C=O;

X² is CR³;

X³ is -NH-;

X⁴ is CR⁴;

X⁵ is CR⁵;

X⁶ is CR⁶;

R¹ is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocycloalkyl, or heteroaryl, provided that when R¹ is alkyl, substituted alkyl or alkenyl, R² is not cyano;

R² is cyano or a substituted or unsubstituted monocyclic heteroaryl group, provided that when R² is cyano R¹ is not alkyl, substituted alkyl or alkenyl;

R³ is hydrogen, hydroxy, halogen, cyano, CO₂R⁷, NR⁸R⁹, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocycloalkyl or heteroaryl;

R⁴, R⁵, and R⁶ are independently selected from the group consisting of hydrogen, halogen, nitro, cyano,

O-R⁷, NR⁸R⁹, SR⁷, S(O)R⁷, SO₂R⁷, SO₃R⁷, SO₂NR⁸R⁹, CO₂R⁷, C(O)NR⁸R⁹, C(O)alkyl,


C(O)substituted alkyl, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl and substituted alkynyl;

US application Serial No. 09/840,503
Attorney Docket No. QA231


R^7 , R^{10} , and R^{11} , are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, C(O)alkyl, C(O)substituted alkyl, C(O)cycloalkyl, C(O) substituted cycloalkyl, C(O)aryl, C(O)substituted aryl, C(O)Oalkyl, C(O)Osubstituted alkyl, C(O)heterocycloalkyl, C(O)heteroaryl, aryl, substituted aryl, heterocycloalkyl and heteroaryl; and

R^8 and R^9 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, alkynyl, C(O)alkyl, C(O)substituted alkyl, C(O)cycloalkyl, C(O)substituted cycloalkyl, C(O)aryl, C(O)substituted aryl, C(O)Oalkyl, C(O)Osubstituted alkyl, C(O)heterocycloalkyl, C(O)heteroaryl, aryl, substituted aryl, heterocycloalkyl, and heteroaryl or R^8 and R^9 taken together with the nitrogen atom to which they are attached complete a heterocycloalkyl or heteroaryl ring; with the following provisos:

- (a) when R^1 is substituted or meta unsubstituted phenyl, R^3 is H, R^4 is H, R^5 is H and R^6 is H, then R^2 is not PhCONH,



- (b) when R^1 is phenyl substituted with H, F, Cl, Br, I, CH₃, CF₃, OH, OCH₃, OCF₃, OCH₂CH₃, NH₂, NHCH₃, N(CH₃)₂, O-benzyl, -C(=O)-R₀, or -C(=O)-OR₀ and R₀ is a lower alkyl group, R^3 is H, R^4 is H, R^5 is H and R^6 is H, then R^2 is not




where Y is CH₂, O or S, m and n are each greater than 1, and the sum of m and n is between 3 and 6; and

- (c) when R^2 is heteroaryl, at least one of the heteroatoms must be O.

11. (canceled)

US application Serial No. 09/840,503
Attorney Docket No. QA231

12. (currently amended) A compound of Claim 10 of formula (III)



(III)

or including enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, and solvates thereof wherein:

R^2 is 4-oxazolyl, substituted 4-oxazolyl, 5-oxazolyl, or substituted 5-oxazolyl;

R^3 is hydrogen, hydroxy, NR^8R^9 , alkyl of 1 to 4 carbons, alkenyl of 2 to 4 carbons, alkynyl of 2 to 4 carbons, substituted alkyl of 1 to 4 carbons, phenyl, substituted phenyl, cycloalkyl of 5 to 7 carbons, substituted cycloalkyl of 5 to 7 carbons, monocyclic heterocycloalkyl and monocyclic heteroaryl;

R^4 is hydrogen, halogen, nitro, hydroxy, alkyl of 1 to 4 carbons, cyano, CF_3 , OCF_3 , OCH_3 , SCH_3 , $S(O)CH_3$, or $S(O)_2CH_3$;

R^5 is hydrogen, halogen, nitro, hydroxy, alkyl of 1 to 4 carbons, cyano, vinyl, CF_3 , CF_2CF_3 , $CH=CF_2$, OCH_3 , OCF_3 , $OCHF_2$, SCH_3 , $S(O)CH_3$, or $S(O)_2CH_3$; and

R^6 is hydrogen, halogen, nitro, hydroxy, alkyl of 1 to 4 carbons, cyano, CF_3 , OCH_3 , OCF_3 , SCH_3 , $S(O)CH_3$, and $S(O)_2CH_3$.

13. (currently amended) A compound of Claim 12 or including enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, and solvates wherein:

R^2 is 4-oxazolyl, substituted 4-oxazolyl, 5-oxazolyl, substituted 5-oxazolyl or heteroaryl;

R^3 is hydrogen, hydroxy, halogen, methyl or NR^8R^9 ;

R^4 is hydrogen;

R^5 is halogen, methyl, ethyl, substituted alkenyl, alkyne, OMe or OCF_3 ; and

R^6 is hydrogen.

US application Serial No. 09/840,503
Attorney Docket No. QA231

14. (currently amended) A compound of Claim 13 ~~or including~~ enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, and solvates wherein:

R^2 is 4-oxazolyl, substituted 4-oxazolyl, 5-oxazolyl or substituted 5-oxazolyl;


R^3 is hydrogen, hydroxy, halogen or methyl;

R^4 is hydrogen;

R^5 is halogen, methyl or OMe; and

R^6 is hydrogen.

15. (currently amended) A compound of Claim 10 of formula (V)




(V)

~~or including~~ enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, and solvates selected from:

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is


US application Serial No. 09/840,503
Attorney Docket No. QA231



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is CH_3 and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is CH_3 ;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231


a compound of formula (V) wherein:

 \mathbb{R}^1 is

and R^3 is hydrogen;


a compound of formula (V) wherein:

\mathbf{R}^1 is




and R³ is hydrogen;

a compound of formula (V) wherein:

 R^1 is

and R³ is hydrogen;

a compound of formula (V) wherein:


 R' is

US application Serial No. 09/840,503
Attorney Docket No. QA231

and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




US application Serial No. 09/840,503
Attorney Docket No. QA231

and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is


US application Serial No. 09/840,503
Attorney Docket No. QA231



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is Br;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

a compound of formula (V) wherein:

US application Serial No. 09/840,503
Attorney Docket No. QA231


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is


US application Serial No. 09/840,503
Attorney Docket No. QA231



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




and R³ is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

a compound of formula (V) wherein:

US application Serial No. 09/840,503
Attorney Docket No. QA231


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is


US application Serial No. 09/840,503
Attorney Docket No. QA231



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is


US application Serial No. 09/840,503
Attorney Docket No. QA231



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is


US application Serial No. 09/840,503
Attorney Docket No. QA231



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




and R³ is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is


US application Serial No. 09/840,503
Attorney Docket No. QA231



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is


US application Serial No. 09/840,503
Attorney Docket No. QA231



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is



and R³ is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




US application Serial No. 09/840,503
Attorney Docket No. QA231

and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

and a compound of formula (V) wherein:





R^1 is








US application Serial No. 09/840,503
Attorney Docket No. QA231

and R³ is hydrogen.





16. (currently amended) A compound of Claim 10 or including enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, and solvates thereof selected from:








US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231








US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231






US application Serial No. 09/840,503
Attorney Docket No. QA231








US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231








US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231




US application Serial No. 09/840,503
Attorney Docket No. QA231




US application Serial No. 09/840,503
Attorney Docket No. QA231



US application Serial No. 09/840,503
Attorney Docket No. QA231



and



17. (previously presented) A pharmaceutical composition comprising a compound of Claim 10 and a pharmaceutically acceptable carrier.
18. (previously presented) A pharmaceutical composition comprising a compound of Claim 11 and a pharmaceutically acceptable carrier.
19. (previously presented) A pharmaceutical composition comprising a compound of Claim 12 and a pharmaceutically acceptable carrier.
20. (previously presented) A pharmaceutical composition comprising a compound of Claim 13 and a pharmaceutically acceptable carrier.
21. (previously presented) A pharmaceutical composition comprising a compound of Claim 14 and a pharmaceutically acceptable carrier.
22. (previously presented) A pharmaceutical composition comprising a compound of Claim 15 and a pharmaceutically acceptable carrier.
23. (previously presented) A pharmaceutical composition comprising a compound of Claim 16 and a pharmaceutically acceptable carrier.

US application Serial No. 09/840,503
Attorney Docket No. QA231

24.-29. (canceled)

30. (previously presented) A method of treating inosine monophosphate dehydrogenase associated disorders comprising: administering a therapeutically effective amount of a compound of claim 10.

31. (previously presented) A method of treating inosine monophosphate dehydrogenase associated disorders comprising: administering a therapeutically effective amount of a compound of claim 11

32. (previously presented) A method of treating inosine monophosphate dehydrogenase associated disorders comprising: administering a therapeutically effective amount of a compound of claim 12.

33. (previously presented) A method of treating inosine monophosphate dehydrogenase associated disorders comprising: administering a therapeutically effective amount of a compound of claim 13.

34. (previously presented) A method of treating inosine monophosphate dehydrogenase associated disorders comprising: administering a therapeutically effective amount of a phosphodiesterase Type 4 inhibitor and a compound of claim 10.

35. (previously presented) A method for the treatment or prevention of allograft rejection comprising: administering a therapeutically effective amount of a phosphodiesterase Type 4 inhibitor and a compound of claim 10.

36. (canceled).

37. (previously presented) A method of claim 34 wherein: the phosphodiesterase Type 4 inhibitor is [4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone].

US application Serial No. 09/840,503
Attorney Docket No. QA231

38. (previously presented) A method of treating inosine monophosphate dehydrogenase associated disorders comprising: administering an therapeutically effective amount of the pharmaceutical composition of Claim 17.

39. (previously presented) A method of treating inosine monophosphate dehydrogenase associated disorders comprising: administering a therapeutically effective amount of the pharmaceutical composition of Claim 17 and another agent known to be useful in treatment of such disorders.

40. (previously presented) A method of treating inosine monophosphate dehydrogenase associated disorders comprising: administering a therapeutically effective amount of the pharmaceutical composition of Claim 17 and a phosphodiesterase Type 4 inhibitor.

41. (previously presented) A method for the treatment or prevention of allograft rejection comprising: administering a therapeutically effective amount of the pharmaceutical composition of Claim 17 and a phosphodiesterase Type 4 inhibitor.
